详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Novel organoid construction strategy for non-involuting congenital hemangioma for drug validation

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China [2]Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu 610041, China [3]Med-X Center for Informatics, Sichuan University, Chengdu 610041, China [4]Institute of Clinical Pathology West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China [5]Department of Hematology, West China Hospital, Sichuan University, Sichuan 610041, China [6]Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [7]Clinical Nutrition Department, West China Hospital of Sichuan University, Chengdu 610041, China [8]Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnocentric of Ministry of Education, Zunyi Medical University, Zunyi, Guizhou 563006, China [9]Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu 610041, China

出处：

DOI：

ISSN：

关键词： Non-involuting congenital hemangiomas Vascular tumor Patient-derived organoids Drug validation

摘要：

Non-involuting congenital hemangiomas (NICHs) are fully formed vascular tumors at birth with distinctive clinical, radiologic, and histopathological profiles. In the literature, there is no effective therapy strategy for patients with NICH except surgery. Currently, no cell line or animal model exists for studying the mechanism of NICH and drug validation. We plan to construct a new strategy by constructing NICH organoids for further study.Here, we report a novel NICH organoid system construction and optimization process. Both HE and immunohistological staining exactly matched NICH tissue. We further performed transcriptome analysis to elucidate the characteristics of NICH organoids. Both NICH tissue and NICH organoids manifested similar trends in download sites. NICH organoids display novel features to new cells derived from organoids and show spectacular multiplication capacity. In the preliminary verification, we found that cells splitting from NICH organoids were human endothelial cells. Drug validation demonstrated that trametinib, sirolimus, and propranolol showed no inhibitory effects on NICH organoids.Our data show that this new NICH-derived organoid faithfully captured the features of this rare vascular tumor. Our study will boost further research on the mechanism of NICH and drug filtering in the future.© 2023. The Author(s).

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区生物学

小类 | 3 区生化研究方法 3 区生物工程与应用微生物

最新[2023]版：

大类 | 3 区生物学

小类 | 3 区生化研究方法 3 区生物工程与应用微生物

第一作者：

第一作者机构： [1]State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu 610041, China

共同第一作者：

通讯作者：

通讯机构： [2]Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu 610041, China [3]Med-X Center for Informatics, Sichuan University, Chengdu 610041, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Novel organoid construction strategy for non-involuting congenital hemangioma for drug validation

文献详情

相关文献